Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney ...

BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to ...

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted BioCity's ...

Albuminuria reduction was greater than for either agent used separately. Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the ...

BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD ...

When the study drugs were discontinued, albuminuria returned to near baseline. Any adverse event (AE) occurred in 52% of the trial population, and serious AEs in 6.1% to 7.1% across arms.

Topline data also show that lorundrostat reduces albuminuria in hypertensive patients with CKD. Topline results from the phase 2 Explore-CKD trial show lorundrostat, an aldosterone synthase ...

BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to ...

Healthy.io, Geisinger and Boehringer Ingelheim Study Reveals Significant Increase in Albuminuria Identification with the Addition of Smartphone Technology. PR Newswire. BOSTON, June 20, 2025.

An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary albumin-to-creatinine ratio (UACR) in patients with albuminuria and both chronic kidney ...